Heart failure treatment developer Cardiac Dimensions announced today that closed a $35 million Series D financing round. Kirkland, Washington-based Cardiac Dimensions develops minimally invasive treatment modalities for heart failure and related cardiovascular conditions. Its lead product, the Carillon Mitral Contour System, uses a gentle, minimally invasive approach. It designed the system to restore natural mitral […]
Cardiac Dimensions Inc.
Cardiac Dimensions touts Carillon TMVR study
Cardiac Dimensions today touted a clinical study of its Carillon mitral contour system in treating the primary cause of functional mitral regurgitation (FRM) in patients with heart failure. Carillon is a right heart transcatheter mitral valve repair (TMVR) device designed to treat FRM in patients with mitral regurgitation grades of 2+, 3+ and 4+ in […]
Cardiac Dimensions touts data from Carillon TMVR device study
Cardiac Dimensions today released results from a trial of its Carillon mitral contour system intended for treating functional mitral regurgitation in patients with heart failure, touting significant reductions in regurgitant volume after implantation. Results from the trial were presented at the German Society of Cardiology annual congress, the Kirkland, Wash.-based company said. The percutaneous Carillon device […]
Aegea Medical picks up former Cardiokinetix, Concentric Medical CEO Sainz | Personnel Moves – May 14, 2018
Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
Cardiac Dimensions anchors $39m Series B for Carillon mitral repair device
Cardiac Dimensions said today that it raised a $39 million Series B round for the Carillon mitral valve repair device it’s developing. Kirkland, Wash.-based Cardiac Dimensions said the round was led by a new Australian backer, Hostplus, and included a venture debt contribution from Oxford Finance. Existing investors M. H. Carnegie, Arboretum Ventures, Lumira Capital, LSP Health […]
FDA approves Cardiac Dimensions trial for Carillon mitral repair device
Cardiac Dimensions said today that the FDA granted an investigational device exemption for a pivotal trial of its Carillon mitral valve repair device. Kirkland, Wash.-based Cardiac Dimensions said the 400-patient study will compare the device with guideline-directed treatment of symptomatic functional mitral regurgitation associated with heart failure after a year. The percutaneous Carillon annuloplasty device is designed […]
Cardiac Dimensions touts small Carillon mitral repair study
Cardiac Dimensions today touted the publication of a small study of its Carillon mitral valve repair system in the Journal of Invasive Cardiology, saying the device led to significant improvement in patients with functional mitral regurgitation. The percutaneous Carillon annuloplasty device is designed to use a distal anchor and proximal anchor, connected by a shaping ribbon, to reshape the […]
Cardiac Dimensions taps ex-AccessClosure chief Casciaro for CEO | Personnel Moves
Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO. Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) […]
Cardiac Dimensions touts cost-utility study of Carillon mitral valve
Cardiac Dimensions said yesterday a new cost-utility study of its Carillon mitral valve shows it to be a cost-effective alternative when compared to optimal medical treatment for treating functional mitral regurgitation. The study was published in the journal BMC Cardiovascular Disorders, and analyzed data from the Titan clinical trial. The study reported an incremental cost-effectiveness ratio […]
Cardiac Dimensions launches clinical trial for Carillon mitral valve device
Cardiac Dimensions today said it launched a clinical trial of its Carillon device, which is designed to treat functional mitral valve regurgitation. The 120-patient Reduce FMR study is a prospective, double-blind, randomized multi-center trial, Kirkland, Wash.-based Cardiac Dimensions said. Patients are slated to be randomized on a 3:1 basis to receive the Carillon device and optimal drug […]
